Investor Relations
For Friulchem, research and development in drug delivery plays a fundamental role “, says our CEO Disma Giovanni Mazzola, in an interview with Market Insight. RS 20.07.2020_Market Insight R&D – ENG
Friulchem S.p.A. is pleased to announce that it has obtained authorization of a new patent application in France for chewable tablets, soon to be extended to other EU and non-EU countries.
Suppleo is the new Italian brand of high-quality complementary feed, with different product lines for specific needs, making its debut on the market choosing the online sales channel. Read more: CS Suppleo Immune System
Friulchem is ready to seize every future opportunity in the animal health sector, which at this time presents excellent growth prospects. This is what Disma Giovanni Mazzola, CEO of Friulchem, declared when asked by MF Dow Jones. Read the complete article: RS 24.06.2020 – MF Dow Jones_EN
Friulchem purchased 13% of the capital of Pharmabbie last March, an American company specialized in the development of veterinary drugs to be distributed in the US market through FC-CUBE technology. Market Insight Pharmabbie
Read the interview of Disma Giovanni Mazzola, Friulchem CEO, released to EconomyMag.
Read the interview of Disma Giovanni Mazzola, Friulchem CEO, released to Market Insight on Vet Business Unit. Fore more information Market Insight veterinary.
Friulchem S.p.A. (AIM: FCM), in compliance with the informative obligations provided for by art. 17 of the AIM Italia Companies Regulations, releases the calendar of company events relative to the 2020 year. Calendar 2020
Friulchem brings Italian quality to China, obtaining from the Chinese Ministry of Agriculture, the registration of a veterinary supplement formulated and produced at its Vivaro plant. New registration in China
Friulchem obtained from Regione FVG the renewal of Vivaro’s Applied Research Laboratory accreditation as a highly skilled facility in the veterinary and human generic drug R&D field.